Abbott 'very cheap' after surprising legal victory validates our conviction
Shares of Abbott Laboratories rose on Friday after the Club holding company scored a surprise victory in a trial into…
investment strategy
Palo Alto Stocks Boosted by Contract News, Abbott Labs Braces for Ruling
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
Danaher puts bioprocessing back into growth. We are raising our rating to buy
Danaher shares fell on Tuesday even though the life sciences company regained growth in its key bioprocessing business in the…
Abbott Labs shines with strong quarter and buyback announcement
Medical device maker Abbott Laboratories on Wednesday delivered better-than-expected quarterly results and raised its profit forecasts for the third consecutive…
Goldman Sachs (GS) earnings in the third quarter of 2024
David Solomon, chairman and CEO of Goldman Sachs, speaking on CNBC's Squawk Box at the World Economic Forum annual meeting…
Health care costs hit post-pandemic highs. Open enrollment movements can help
About 165 million Americans get their health insurance through work, yet most don't spend much time considering what their employer…
JPM's Dimon says geopolitical risks are 'treacherous and getting worse'
JPMorgan Chase CEO and Chairman Jamie Dimon speaks during the US Senate Banking, Housing and Urban Affairs Committee's oversight hearing…
Ozempic raises healthcare costs, whether you can get it or not
About 165 million Americans rely on employer-sponsored health insurance, and yet workers still may not get the coverage they want,…
Banks still unclear
Federal Reserve Board Chairman Jerome Powell holds a news conference following a two-day meeting of the Federal Open Market Committee…
Recursion Gets FDA Approval to Begin Phase 1 Trials of AI-Discovered Cancer Treatment
Source: Recursion Pharmaceuticals Pioneer in AI drugs Recursion Pharmaceuticals said Wednesday that one of its experimental treatments has reached a…